Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1791 results
May 2021
-
Press Release
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999With other innovations, the Novartis artemisinin-based… -
Press Release
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by… -
Featured News
World Asthma Day 2021
Understanding asthma: What are your misconceptions? This World Asthma Day find out more about asthma and challenge your misconceptions.
-
Story Access to Healthcare
Fighting MS through innovation
Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).
-
Press Release
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1Neovascular age-related macular degeneration accounts… -
Story Patient Perspectives
From melanoma survivor to front-line nurse
Jordan, a melanoma survivor, shares her experience with melanoma, BRAF mutation testing and the importance of patient empowerment.
-
Press Release
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic…
April 2021
-
Ad-hoc Release
Novartis: moteurs clés de la croissance et lancements poursuivent leur essor au 1er trimestre, maintenant la confiance dans la croissance. Confirmation des prévisions pour le Groupe pour 2021
Chiffre d’affaires net du T1 en recul de -2% (tcc¹, +1% USD), impacté par les achats anticipés au T1 2020 en lien avec le Covid-19 (env. USD 0,4 milliard) Pharmaceuticals: le chiffre d’affaires… -
Ad-hoc Release
Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
Der Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb… -
Ad-hoc Release
Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion) Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with… -
Featured News
World Malaria Day 2021
This year, World Malaria Day is running with the backdrop of countries around the world continuing to fight the COVID-19 pandemic.
-
Press Release
Novartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience
SMART study to extend data beyond patient population studied in clinical trials New clinical study to evaluate safety and efficacy of Zolgensma in children up to 21 kg, adding to real-world…